Restaurants company Jubilant Foodworks announced Q2FY26 results The Group System Sales came in at Rs 27,465 million. The Group store network expanded to 3,480 stores at the end of the period, with net addition of 93 stores. Revenue from operations increased 19.7% YoY to Rs 23,402 million. EBITDA increased 19.5% YoY to Rs 4,762 million; EBITDA margin steady at 20.3%. Pre-Ind AS EBITDA increased 18.5% YoY to Rs 3,244 million and pre-Ind AS EBITDA margin of 13.9%. PAT from continued operations before exceptional items increased 53.7% YoY to Rs 1,099 million and PAT margin expanded 104bps YoY to 4.7%. Shyam S. Bhartia, Chairman & Hari S. Bhartia, Co-Chairman, Jubilant FoodWorks, said: “We are delighted with the steady topline growth across all markets. Our India business continues to grow ahead of the market while also witnessing a consistent improvement in operating margin and PAT margin. Our Turkey business is consistently delivering value accretion with robust topline growth and healthy PAT margin. Sri Lanka and Bangladesh businesses are also witnessing strong growth. Overall, our strong performance and the momentum generated in H1, we believe, has set JFL for a very promising H2” Sameer Khetarpal, CEO & MD of Jubilant FoodWorks, said: "This has truly been a dream quarter for JFL. Domino’s delivered robust like-for-like growth across all geographies, while Popeyes achieved double-digit same-store sales growth. Domino’s India became the first QSR brand to reach 500 cities and JFL further expanded its PAT margin. Additionally, Domino’s India launched an app monetisation platform, partnering with leading national brands and opening up new revenue streams for the company." Result PDF
Consumer Electronics company Voltas announced Q2FY26 results Consolidated Total Income of Rs 2,412 crore, compared to Rs 2,725 crore in Q2FY25. Profit Before Tax of Rs 54 crore vs Rs 205 crore in Q2FY25. Net Profit of Rs 32 crore compared to Rs 133 crore Q2FY25. Mukundan Menon C P, Managing Director, Voltas, said: “The second quarter of FY26 was marked by external challenges, but our fundamentals remain strong. The GST reduction and upcoming BEE efficiency transition will unlock pent-up consumer demand in upcoming quarters. Our integrated strategy, diversified portfolio, combining product innovation, manufacturing excellence, and channel revitalisation, positions us well for sustainable growth and value creation”. Result PDF
Apparels & Accessories company Page Industries announced Q2FY26 results Sales volume growth was 2.5% YoY, amounting to 56.6 million pieces. Revenue was Rs 12,909 million, growth of 3.6% YoY. EBITDA was Rs Rs 2,795 million, a decline of 0.7% YoY. Profit After Tax (PAT) was Rs 1,948 million with a decline of 0.3% YoY. V.S. Ganesh, Managing Director, Page Industries, said: “Our continued focus on operational efficiency and cost optimisation measures while investing in product innovation and distribution expansion has contributed to strong operating margins. While revenue growth was moderate this quarter, we are well-positioned to capitalise on the improvement in demand in the coming months. Result PDF
Pharmaceuticals company Alkem Laboratories announced Q2FY26 results Total Revenue from Operations was Rs 40,010 million, with YoY growth of 17.2%. India sales were Rs 27,660 million, YoY growth of 12.4%. International sales were Rs 11,890 million, with YoY growth of 29.5%. Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) were Rs 9,208 million, resulting in an EBITDA margin of 23.0% vs 22.0% in Q2FY25. EBITDA grew by 22.3% YoY. R&D; expenses for Q2FY26 were Rs 1,302 million, or 3.3% of total revenue from operations, vs Rs 1,465 million in Q2FY25 at 4.3% of total revenue from operations. Profit before tax was Rs 8,958 million, YoY growth of 14.8%. Net Profit (after Minority Interest) was Rs 7,651 million, YoY growth of 11.1%. According to IQVIA (SSA) data, for Q2FY26: In the Acute segment, Alkem became the number one company in IPM this quarter. The Company registered a growth of 6.4% YoY in-line with the Indian Pharmaceutical Market (IPM), which also grew by 6.4%. Vikas Gupta, CEO, Alkem, said: “Q2FY26 has been another strong quarter for us, marked by robust growth across India, the US, and key international markets. We also saw healthy traction in new product launches across markets. The GST revision is a positive step, and we adapted swiftly to ensure a seamless transition. Our improved gross margins and operating leverage have contributed to a stronger EBITDA profile. As we look ahead, we remain focused on accelerating growth and continue to strengthen our presence in key markets.” Result PDF
Pharmaceuticals company Ipca Laboratories announced Q2FY26 results Consolidated Net total Income up 9% at Rs 2,584.36 crore. Consolidated EBITDA margin (before forex (gain)/loss, other income and exceptional items) @ 21.68% in Q2FY26 as against @ 19.10% in Q2FY25. Consolidated Net Profit at Rs 282.57 crore (after exceptional items) up 23%. Exports Income up 7% at Rs 813.65 crore. Indian formulations income up 8% at Rs 1018.90 crore. Result PDF